Evolve BioSystems, Inc., a Davis, CA-based microbiome company committed to developing novel solutions to restore and maintain a healthy newborn gut microbiome, completed a $20m Series B funding.
The round was led by Spruce Capital Partners/MLS with participation from existing shareholders Horizons Ventures and Tate & Lyle Ventures and new investors Bow Capital and Acre Venture Partners.
The company will use the funds for ongoing clinical activities, operational expansion, and the launch of its activated probiotic and prebiotic products, which restore the infant gut microbiome to its natural state, allowing proper metabolic and immune development, and for the development and commercialization of additional animal health products, which aim to restore the balance of nursing animals’ microbiome.
Led by Dr. David Kyle, CEO, Evolve BioSystems develops products to establish, restore, and maintain a healthy human gut microbiome. The company, a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis, is now applying its discovery platform to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions to support the lifelong health of newborns worldwide.